Literature DB >> 35600172

Resistant hypertension and PRES syndrome induced by carbamazepine in a patient with SLE: A case report and literature review.

Mohammad Alsultan1, Kassem Basha2.   

Abstract

Introduction: Several conditions of resistant hypertension (RHTN) have been suggested and are often associated in the same patient. Approximately 75% of patients with posterior reversible encephalopathy syndrome (PRES) have moderate to severe HTN at presentation. Case presentation: A 26- year old SLE-patient presented with seizures followed by confusion and cortical blindness, in the context of emergent HTN and MRI revealed PRES syndrome. However, antihypertensive drugs were increased to maximum doses with two HD sessions, the patient still had high measures of BP. The dilemma was to find the underlying cause of long-term RHTN in this patient, where several etiologies were implicated. We review the status in more specific details and draw a timeline, which showed constant exposer to carbamazepine from the beginning of HTN. Thereafter, converting the patient to levetiracetam resulted in resolving the RHTN. Discussion/conclusion: We discuss this case with a literature review over the past ten years, which shows only three patients with a neurologic deficit in the context of severe HTN induced by carbamazepine. In the end, determining the secondary etiology of RHTN, in this patient, is considered a diagnosis of challenge due to the coincidence with SLE and the rarity of this side effect of carbamazepine. This is considered a valuable message to always exclude all secondary causes, especially drugs effects, in ESRD-patients with multiple comorbidities.
© 2022 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.

Entities:  

Keywords:  Carbamazepine; ESRD; Posterior reversible encephalopathy syndrome; Resistant hypertension; SLE

Year:  2022        PMID: 35600172      PMCID: PMC9117529          DOI: 10.1016/j.amsu.2022.103767

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


  17 in total

1.  Carbamazepine decreases antihypertensive effect of nilvadipine.

Authors:  Norio Yasui-Furukori; Tomonori Tateishi
Journal:  J Clin Pharmacol       Date:  2002-01       Impact factor: 3.126

2.  Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine.

Authors:  Y Akamine; H Uehara; M Miura; N Yasui-Furukori; T Uno
Journal:  J Clin Pharm Ther       Date:  2015-05-26       Impact factor: 2.512

3.  Carbamazepine-Induced Uncontrolled Hypertension.

Authors:  Aamer Ubaid; Farishta Waheed; Saadia Waheed
Journal:  Am J Ther       Date:  2020 Nov/Dec       Impact factor: 2.688

4.  Increased Incidence of Resistant Hypertension in Patients With Systemic Lupus Erythematosus: A Retrospective Cohort Study.

Authors:  Jocelyn S Gandelman; Omair A Khan; Megan M Shuey; Jacquelyn E Neal; Elizabeth McNeer; Alyson Dickson; April Barnado; Li Wang; Prathima Anandi; William D Dupont; C Michael Stein; Cecilia P Chung
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04       Impact factor: 4.794

5.  [A new cause of resistant arterial hypertension: coprescription with anticonvulsant treatments].

Authors:  P Iaria; J Blacher; M Asplanato; K Edric; M Safar; X Girerd
Journal:  Arch Mal Coeur Vaiss       Date:  1999-08

6.  Carbamazepine clearance in hemodialysis and hemoperfusion.

Authors:  R J Kandrotas; K S Oles; P Gal; J M Love
Journal:  DICP       Date:  1989-02

7.  Carbamazepine- induced hypertension.

Authors:  Nathalie Jette; Tim Veregin; Alan Guberman
Journal:  Neurology       Date:  2002-07-23       Impact factor: 9.910

8.  Transient neurologic deficits associated with carbamazepine-induced hypertension.

Authors:  Ann M Marini; John Y Choi; Robert J Labutta
Journal:  Clin Neuropharmacol       Date:  2003 Jul-Aug       Impact factor: 1.592

9.  [Arterial hypertension caused by carbamazepine].

Authors:  G P Bo; L Cocito; M Maffini; P Perfumo; S Venturi
Journal:  Riv Neurol       Date:  1987 Nov-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.